Cytodyn Inc (CYDY)

[hitekmastr]

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, stated, “In the mild- to-moderate population, it is important to have a therapeutic option for COVID-19 in patients who are showing signs of rapid clinical deterioration. Patients receiving leronlimab showed a statistically significant improvement using NEWS2 clinical parameters. We will make a case for IMMEDIATE APPROVAL of leronlimab for this population of COVID-19 patients, not only in the U.S., but in the U.K. and other countries around the world.”